[HTML][HTML] Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss, Q Zhang… - Nature …, 2022 - nature.com
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

[HTML][HTML] Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss… - Nature …, 2022 - ncbi.nlm.nih.gov
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

[PDF][PDF] Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss, Q Zhang… - scienceopen.com
Cell dimensions: a, b, c (Å) 55.02, 81.22, 88.83 α, β, γ () 90, 96.7, 90 Resolution (Å) 44.04–
2.20 (2.32–2.20) 59.75–1.85 (1.92–1.85) No. reflections measured 48579 (5302) 171591 …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.

DW Kneller, G Phillips, KL Weiss, Q Zhang… - 2022 - cabidigitallibrary.org
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss… - Nature …, 2022 - ideas.repec.org
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss… - Nature …, 2022 - ui.adsabs.harvard.edu
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss… - Nature …, 2022 - econpapers.repec.org
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.

DW Kneller, H Li, G Phillips, KL Weiss… - Nature …, 2022 - search.ebscohost.com
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease...

ornl.gov
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …

Covalent narlaprevir-and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

DW Kneller, H Li, G Phillips, KL Weiss, Q Zhang… - Nature …, 2022 - osti.gov
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19
vaccines, and small-molecule antivirals can provide an important therapeutic treatment …